Additionally, to better guide the development of HFn nanocages as drug-targeted delivery systems for AML therapy, we analyzed the expression of TFRC in AML cells in many clinical scenarios using the data obtained from the GEO database. The gene discussed is TFRC; the disease is acute myeloid leukemia.